A Phase II Study of Duvelisib in Patients with Recurrent or Persistent Peripheral T-Cell Lymphoma

Full Title

PAC PROTOCOL: A Multi- Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Purpose

The purpose of this study is to assess the safety and effectiveness of three different doses of the investigational drug duvelisib in patients with peripheral T-cell lymphoma (PTCL) that has come back or continued to grow despite prior therapy. Duvelisib works by blocking the activity of an enzyme called PI3 kinase (PI3K), which transmits signals between cells and helps to control cell growth.

PI3K is overproduced by some cancers, which can fuel cancer growth. The activity of PI3K is known to be increased in many blood cancers, including PTCL. Duvelisib is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have PTCL that has come back or continued growing despite at least two prior regimens of therapy.
  • Patients should recover from the serious side effects of previous treatments before entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Steven Horwitz at 212-639-3045.

Protocol

18-377

Phase

II

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators